Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 5:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 7,764 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo; placebo comparator condition Clear all
Recruiting Phase 3 Interventional

Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder

NCT06830044
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Milsaperidone, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
29
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Garden Grove, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 13, 2026, 5:14 PM EDT
Completed Not applicable Interventional Results available

Bone Health in Pediatric Crohn's Disease: A Low Magnitude Mechanical Stimulus Trial

NCT00364130
View directory record Official record
Conditions
Crohn Disease
Interventions
Low magnitude mechanical stimulus, Placebo (inactive) low magnitude mechanical stimulus
Device
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
8 Years to 21 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 14, 2017 · Synced Oct 13, 2026, 5:14 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

NCT02543567
View directory record Official record
Conditions
Healthy
Interventions
Ad26.ZEBOV 5*10^10 viral particles (vp), Ad26.ZEBOV 2*10^10 (vp), Ad26.ZEBOV 0.8*10^10 (vp), MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.], MVA-BN-Filo 5*10^7 Inf. U., Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
525 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
6
States / cities
Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 13, 2026, 5:14 PM EDT
Active, not recruiting Phase 3 Interventional

A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

NCT05648500
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Cenerimod, Placebo
Drug
Lead sponsor
Viatris Innovation GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
22
States / cities
Huntington Park, California • Aurora, Colorado • Clearwater, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 13, 2026, 5:14 PM EDT
Completed Phase 3 Interventional Results available

PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT03618030
View directory record Official record
Conditions
ADHD
Interventions
PRC-063 oral capsules, Placebo oral capsules
Drug
Lead sponsor
Purdue Pharma, Canada
Industry
Eligibility
18 Years to 60 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
8
States / cities
Bradenton, Florida • Lakeland, Florida • Maitland, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Oct 13, 2026, 5:14 PM EDT
Not listed Not applicable Interventional

A Cognitive Bias Modification RCT for Aggression

NCT04819230
View directory record Official record
Conditions
Intermittent Explosive Disorder
Interventions
Cognitive Bias Modification, Cognitive Bias Control
Behavioral
Lead sponsor
Temple University
Other
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Oct 13, 2026, 5:14 PM EDT
Completed Phase 4 Interventional Results available

Tamsulosin for Urolithiasis in the Emergency Dept

NCT00382265
View directory record Official record
Conditions
Ureterolithiases
Interventions
tamsulosin, Placebo
Drug · Other
Lead sponsor
Andrew Meltzer
Other
Eligibility
18 Years and older
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
4
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2018 · Synced Oct 13, 2026, 5:14 PM EDT
Terminated Phase 2 Interventional Results available

NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)

NCT04442230
View directory record Official record
Conditions
Coronavirus Infection
Interventions
NasoVAX, Placebo
Biological · Other
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Miami, Florida • Morrow, Georgia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 13, 2026, 5:14 PM EDT
Recruiting Phase 2 Interventional

Intravenous Ketamine for Treatment-Resistant Depression

NCT06668571
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD)
Interventions
Ketamine, Normal Saline
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 13, 2026, 5:14 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.

NCT00696436
View directory record Official record
Conditions
Hypertension
Interventions
Azilsartan medoxomil, Valsartan, Olmesartan, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
86
States / cities
Alabaster, Alabama • Ozark, Alabama • Green Valley, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2011 · Synced Oct 13, 2026, 5:14 PM EDT
Completed Phase 1 Interventional

Safety & Tolerability Study of CTP-499 in Patients With Moderate Chronic Kidney Disease

NCT01460199
View directory record Official record
Conditions
Stage 3 Chronic Kidney Disease
Interventions
CTP-499, placebo
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
3
States / cities
Costa Mesa, California • Garden Grove, California • Tustin, California
Source: ClinicalTrials.gov public record
Updated May 24, 2013 · Synced Oct 13, 2026, 5:14 PM EDT
Completed Not applicable Interventional Results available

Seizure Activity in Alzheimer's Disease

NCT01554683
View directory record Official record
Conditions
Alzheimer's Disease, Seizures
Interventions
Low/High/Placebo Dose Keppra (Levetiracetam)
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
50 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Oct 13, 2026, 5:14 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease

NCT02760602
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Solanezumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 85 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
98
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 80 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Oct 13, 2026, 5:14 PM EDT
Completed Phase 3 Interventional Results available

A Study in Prevention of Re-emergence of Depression Symptoms

NCT01299272
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY2216684, Placebo, SSRI
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
27
States / cities
Redlands, California • Sherman Oaks, California • Wildomar, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 13, 2026, 5:14 PM EDT
Terminated Phase 2 Interventional Results available

ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )

NCT03938545
View directory record Official record
Conditions
Graves' Ophthalmopathy (GO)
Interventions
RVT-1401 (Administered via subcutaneous injection), Placebo (Administered via subcutaneous injection)
Drug · Other
Lead sponsor
Immunovant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
12
States / cities
Beverly Hills, California • Pasadena, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Oct 13, 2026, 5:14 PM EDT
Completed Phase 3 Interventional

Zestra in Women With Mixed Sexual Dysfunction

NCT00118495
View directory record Official record
Conditions
Sexual Dysfunction, Psychological
Interventions
Non-prescription Zestra(TM): patented formulation
Drug
Lead sponsor
QualiLife Pharmaceuticals
Industry
Eligibility
21 Years to 65 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
13
States / cities
Tarzana, California • Aurora, Colorado • Aventura, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2007 · Synced Oct 13, 2026, 5:14 PM EDT
Recruiting Not applicable Interventional

Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic Leukemia

NCT07191119
View directory record Official record
Conditions
Survivor of Childhood Cancer, Insomnia, Acute Lymphoblastic Leukemia (ALL)
Interventions
Soterix tVNS device, Soterix tVNS device (sham programmed), Sleep Quality, Neurocognitive and mental health outcomes
Device · Behavioral
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
20 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 13, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease

NCT05499130
View directory record Official record
Conditions
Crohn Disease, Colitis, Ulcerative
Interventions
TEV-48574, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
36
States / cities
Sun City, Arizona • San Diego, California • Kissimmee, Florida + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 13, 2026, 5:14 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)

NCT04939428
View directory record Official record
Conditions
Coronavirus Disease (COVID-19)
Interventions
Molnupiravir, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
2,441 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
59
States / cities
Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Oct 13, 2026, 5:14 PM EDT
Terminated Phase 3 Interventional Results available

An Efficacy and Safety Study of Ravulizumab in ALS Participants

NCT04248465
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, ALS
Interventions
Placebo, Ravulizumab
Drug · Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
34
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Loma Linda, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Oct 13, 2026, 5:14 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease

NCT06826612
View directory record Official record
Conditions
Huntington Disease
Interventions
SPK-10001, Placebo Surgery Control
Genetic · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
25 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
5
States / cities
Boston, Massachusetts • Cincinnati, Ohio • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 13, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease

NCT00812565
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo, octagam 10%
Drug · Biological
Lead sponsor
Octapharma
Industry
Eligibility
50 Years to 85 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Hoboken, New Jersey
Source: ClinicalTrials.gov public record
Updated May 5, 2014 · Synced Oct 13, 2026, 5:14 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Citicoline in Youth Alcohol Use Disorder

NCT05870111
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Citicoline (cytidine diphosphate-choline), Placebo oral capsule
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
16 Years to 22 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 13, 2026, 5:14 PM EDT
Not listed Not applicable Interventional

Combination of Active or Placebo Attentional Bias Modification Treatment (ABMT) to Either Cognitive Behavioral Group Therapy (CBGT) or Psychoeducational Control Intervention (PCI) for Anxiety Disorders in Children

NCT01687764
View directory record Official record
Conditions
Generalized Anxiety Disorder, Separation Anxiety Disorder, Social Anxiety Disorder
Interventions
Attentional Bias Modification Treatment (ABMT) - Active, Attentional Bias Modification Treatment - Placebo, Cognitive Behavioral Group Therapy, Psychoeducational Control Intervention
Other · Behavioral
Lead sponsor
Hospital de Clinicas de Porto Alegre
Other
Eligibility
7 Years to 11 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 19, 2012 · Synced Oct 13, 2026, 5:14 PM EDT